.png%3Fv%3D63861899706&w=96&q=100){kind=small}
BioShares covers East to West cellular therapy launch with Speculative Buy - Class B rating
Industry commentators, BioShares, recently covered AdCella's collaboration with Shanghai Cell Therapy Group to advance the ground-breaking armoured CAR-T product BZDS1901 into Phase 1b clinical trials in Australia and giving AdAlta a "Speculative Buy - Class B" rating.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be visible to everyone.
Investor Q&As
Start the conversation
Ask AdAlta a question about this update.